

Suppl. Figure 1



Suppl. Figure 2

Suppl. Figure 1 ***Cytokine/chemokines in plasma samples following s.c. injection of 30 mg in three MRCC patients.*** Quantitative measurement of IFN-γ, IL-6, TNF-α, Eotaxin/CCL11, Eotaxin-3/CCL26, IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, MCP-4/CCL13, MDC/CCL22, MIP-1β/CCL4 and TARC/CCL17 in undiluted plasma samples pre-dosing and at 0.5, 1, 2, 4 and 24 hrs following injection of the first dose of 30 mg IMP321 s.c., as determined using an electro-chemiluminescence assay. The limit of detection for IFN-γ is 2.9 pg/ml, IL-6 0.17 pg/ml, TNF-α 0.36 pg/ml, Eotaxin 39 pg/ml, Eotaxin-3 15 pg/ml, IL-8 0.7 pg/ml, IP-10 28 pg/ml, MCP-1 5 pg/ml, MCP-4 58 pg/ml, MDC 116 pg/ml, MIP-1β 23 pg/ml and TARC 54 pg/ml. The baseline for patient 19 and the 2 hrs-time points for patient 21 were missing on the time of the assay.

Suppl. Figure 2 ***Anti-IMP321 antibodies.*** Serum collected at baseline and 2 weeks after the third and the sixth injection of each IMP321 dose are tested for the presence of anti-IMP321 antibody by direct ELISA. Absorbance values corresponding to various concentration of an anti-IMP321 recombinant human $(Fab')_2$ antibody fragment (left panel) are indicated. The data from dropped-out patients (Patient #8, #12 and #17) are not presented.

Adverse events associated with treatment

Grade 1 (injection site)	0.05 mg	0.25 mg	1.25 mg	6.25 mg	30 mg*
Induration	0	1	0	0	0
Erythema	0	1	1	0	8
Nodule	0	0	0	0	2
Oedema	0	0	1	0	1
Pain	0	0	0	0	2

* The 30 mg dose was split in four distinct injections sites. The number of injection sites under study is therefore 24 per patient and not only 6 as for the other groups.

Suppl. Table 1.